Evidence map›Paper›PMID 30111308›Full record

ArticleBMC health services research2018

Moving low value care lists into action: prioritizing candidate health technologies for reassessment using administrative data.

Lesley J J Soril, Brayan V Seixas, Craig Mitton, Stirling Bryan, Fiona M Clement

Abstract read
In one paragraph

Article in BMC health services research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Addressing the overuse-underuse paradox in healthcare.Medicine, health care, and philosophy · 2025
    Article
  2. A method to identify prescription drug targets for health technology reassessment.International journal of technology assessment in health care · 2025
    Article
  3. Article
  4. Article
  5. Developing a How-to-Guide for Health Technology Reassessment: "The HTR Playbook".International journal of health policy and management · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Expanding disease and undermining the ethos of medicine.European journal of epidemiology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lesley J J SorilDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Brayan V SeixasCentre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada.
Craig MittonCentre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada.
Stirling BryanCentre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, BC, Canada.
Fiona M ClementDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. fclement@ucalgary.ca.

Funding

Alberta Innovates - Health Solutions Graduate Studentship Award 201500076Health Technology Review, Province of British Columbia 2016-185
6 · The paper itself

Abstract

backgroundActive management of existing health technologies (e.g., devices, diagnostic, and/or medical procedures) to ensure the delivery of high value care is increasingly recognized around the world. A number of initiatives have raised awareness of technologies that may be overused, mis-used, or potentially harmful by compiling them into lists of low value care. However, despite the growing number of lists, changes to local healthcare practices remain challenging for many systems. The objective of this study was to develop and implement a process, leveraging existing initiatives and data assets, to produce a list of prioritized low value technologies for health technology reassessment (HTR).

methodsAn expert advisory committee comprised of clinical experts and health system decision-makers was convened to determine key process requirements. Once developed, the process was piloted to assess feasibility in the Canadian province of British Columbia (BC).

resultsThe expert advisory committee identified five required attributes for the process: data-driven, routine and replicable, actionable, stakeholder collaboration, and high return on investment. Guided by these attributes, a 5-step process was developed. First, over 1300 published low value technologies (i.e., from the National Institute for Health and Care Excellence [NICE] "do not do" recommendations, low value technologies in the Australian Medical Benefits Schedule, and Choosing Wisely "Top 5" lists) were identified. Using appropriate coding systems for BC's administrative health data (e.g., International Classification of Diseases [ICD]), the low value technologies were queried to examine frequencies and costs of technology use. This information was used to rank potential candidates for reassessment based on high annual budgetary impact. Lastly, clinical experts reviewed the ranked technologies prior to broad dissemination and stakeholder action. Pilot testing of the process in BC resulted in the prioritization of 9 initial candidate technologies for reassessment.

conclusionsThis is the first account of a systematic approach to move a collective body of low value technology recommendations into action in a healthcare setting. This work demonstrates the feasibility and strength of using administrative data to identify and prioritize low value technologies for HTR at a population-level.

Indexed as

Quality of Health CareAdvisory CommitteesAustraliaBiomedical TechnologyBritish ColumbiaDelivery of Health CareDiffusion of InnovationFeasibility StudiesHumansResearch ReportTechnology Assessment, BiomedicalAdministrative health datade-adoptionde-implementationDisinvestmentHealth technology reassessmentLow value care

Identifiers

PMID30111308
PMCPMC6094474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.